Procainamide-induced hemolytic anemia.
The paper reports a case of hemolytic anemia induced by procainamide hydrochloride treatment. Decreases in hemoglobin concentration are correlated with 11 months of procainamide treatment along with a marked increase in hemoglobin following cessation of the drug. The patient exhibited no symptoms suggestive of drug-induced Lupus Erythematosus that has been frequently reported as a sequela of procainamide therapy. Direct antiglobulin tests were consistently positive throughout the clinical course, and an ether-eluate prepared from the patient's red blood cells showed panagglutinability. The antibody in the eluate reacted with Rhnull, D--, LW negative, and U negative red blood cells without addition of procainamide or pretreatment of red blood cells with the drug. It is noted that this antibody reacts similarly to the antibody produced as a consequence of alpha-methyl-dopa therapy.
D000017:ABO Blood-Group System; D000368:Aged; D000743:Anemia, Hemolytic / Q000139:chemically induced* / Q000276:immunology; D003298:Coombs Test; D006801:Humans; D008297:Male; D011342:Procainamide / Q000009:adverse effects*; D012204:Rh-Hr Blood-Group System
D000017:ABO Blood-Group System; D012204:Rh-Hr Blood-Group System; D011342:Procainamide